TrueMark Investments LLC Has $9.86 Million Stock Position in Novo Nordisk A/S $NVO

TrueMark Investments LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 20.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 193,853 shares of the company’s stock after buying an additional 33,437 shares during the period. Novo Nordisk A/S makes up 1.9% of TrueMark Investments LLC’s portfolio, making the stock its 10th biggest position. TrueMark Investments LLC’s holdings in Novo Nordisk A/S were worth $9,863,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cox Capital Mgt LLC boosted its holdings in shares of Novo Nordisk A/S by 7.0% in the fourth quarter. Cox Capital Mgt LLC now owns 26,900 shares of the company’s stock valued at $1,369,000 after acquiring an additional 1,768 shares in the last quarter. InTrack Investment Management Inc raised its holdings in Novo Nordisk A/S by 9.4% during the fourth quarter. InTrack Investment Management Inc now owns 8,480 shares of the company’s stock worth $431,000 after purchasing an additional 726 shares in the last quarter. Bond & Devick Financial Network Inc. raised its holdings in Novo Nordisk A/S by 3.7% during the fourth quarter. Bond & Devick Financial Network Inc. now owns 15,422 shares of the company’s stock worth $785,000 after purchasing an additional 550 shares in the last quarter. A. D. Beadell Investment Counsel Inc. lifted its position in Novo Nordisk A/S by 4.7% in the fourth quarter. A. D. Beadell Investment Counsel Inc. now owns 35,833 shares of the company’s stock worth $1,823,000 after purchasing an additional 1,605 shares during the period. Finally, Southland Equity Partners LLC lifted its position in Novo Nordisk A/S by 7.1% in the fourth quarter. Southland Equity Partners LLC now owns 7,525 shares of the company’s stock worth $383,000 after purchasing an additional 502 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Awiqli (insulin icodec‑abae), the first once‑weekly basal insulin for adults with type 2 diabetes — expands treatment choices, may improve adherence vs daily basal insulin and supports a U.S. launch in the second half of 2026. US FDA approves Novo’s insulin injection for type 2 diabetes
• Positive Sentiment: Corporate governance/market strategy bolstered by appointment of Mars CEO Poul Weihrauch as a board observer — intended to strengthen Novo’s positioning and commercial insights in the competitive U.S. obesity market. Novo Nordisk appoints Mars CEO as board observer
• Neutral Sentiment: Filed updated Articles of Association and capital‑increase mandate — routine corporate housekeeping that can enable share issuance or compensation plans but has no immediate earnings impact. Articles of Association for Novo Nordisk A/S 2026
• Neutral Sentiment: Mixed analyst coverage: Wolfe Research started coverage with a “peer perform” rating and some brokers give neutral takes on the pipeline — underscores divergent views on growth sustainability vs valuation.
• Neutral Sentiment: Pipeline commentary: promising signals for next‑generation candidates (e.g., UBT251 triple‑agonist) but analysts flag that new oral drug trends and incremental data so far are not yet transformative. GLP‑1 pipeline shows promise but oral drug trends give analysts pause
• Negative Sentiment: Bernstein initiated coverage with an Underperform rating and a low price target, warning the company’s earnings downgrade cycle may not be over — a clear near‑term headwind for sentiment and the stock. Bernstein initiates coverage with Underperform
• Negative Sentiment: Recent headlines and analyst notes have coincided with share weakness and short‑term selling — valuation concerns (forward P/E in the low double digits vs peers) and profit‑taking after prior rallies are weighting the stock. Stock slides as market rises

Novo Nordisk A/S Trading Down 0.1%

Novo Nordisk A/S stock opened at $36.01 on Monday. The firm has a market cap of $160.78 billion, a price-to-earnings ratio of 10.38, a price-to-earnings-growth ratio of 8.52 and a beta of 0.73. Novo Nordisk A/S has a 1 year low of $35.85 and a 1 year high of $81.44. The firm’s 50 day moving average price is $45.92 and its two-hundred day moving average price is $50.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a dividend yield of 708.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 52.74%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Citigroup began coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research note on Tuesday, March 3rd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Four investment analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.